Search research articles
Contact Us
Filters
Showing results (41-50 of 138) with videos related to
Page
of 14
Sort By:
Psychopharmacology
|
December 17, 2013
Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects
Andrew H Kemp, Tim Outhred, Sasha Saunders, et al.
The International Journal of Neuropsychopharmacology
|
January 21, 2004
Selective effects of simultaneous monoamine depletion on mood and emotional responsiveness
Jay-Maree Hughes, Cathy Matrenza, Andrew H Kemp, et al.
The International Journal of Neuropsychopharmacology
|
June 1, 2012
Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex
Chandra Sekhar Sripada, K Luan Phan, Izelle Labuschagne, et al.
Human Psychopharmacology
|
January 16, 2008
An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: effects of citalopram, escitalopram and sertraline
Valérie Guille, Rodney J Croft, Barry V O'Neill, et al.
Drug Discovery Today
|
January 24, 2021
Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development
Alette M Wessels, Chris J Edgar, Pradeep J Nathan, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 3, 2011
Cognitive effort drives workspace configuration of human brain functional networks
Manfred G Kitzbichler, Richard N A Henson, Marie L Smith, et al.
Psychopharmacology
|
July 25, 2007
High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans
Barry V O'Neill, Rodney J Croft, Sumie Leung, et al.
Drug Discovery Today
|
September 10, 2019
Cholinergic muscarinic M<sub>1</sub> and M<sub>4</sub> receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
Daniel Erskine, John-Paul Taylor, Geor Bakker, et al.
Hormones and Behavior
|
August 19, 2008
Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women
Cali F Bartholomeusz, Keith A Wesnes, Jayashri Kulkarni, et al.
Drug Discovery Today
|
November 28, 2015
Assessment of cognitive safety in clinical drug development
Jonathan P Roiser, Pradeep J Nathan, Adrian P Mander, et al.
Page
of 14
Search research articles
Search
Showing results (41-50 of 138) with videos related to
Sort By:
Page
of 14
Psychopharmacology
|
December 17, 2013
Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects
Andrew H Kemp, Tim Outhred, Sasha Saunders, et al.
The International Journal of Neuropsychopharmacology
|
January 21, 2004
Selective effects of simultaneous monoamine depletion on mood and emotional responsiveness
Jay-Maree Hughes, Cathy Matrenza, Andrew H Kemp, et al.
The International Journal of Neuropsychopharmacology
|
June 1, 2012
Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex
Chandra Sekhar Sripada, K Luan Phan, Izelle Labuschagne, et al.
Human Psychopharmacology
|
January 16, 2008
An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: effects of citalopram, escitalopram and sertraline
Valérie Guille, Rodney J Croft, Barry V O'Neill, et al.
Drug Discovery Today
|
January 24, 2021
Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development
Alette M Wessels, Chris J Edgar, Pradeep J Nathan, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 3, 2011
Cognitive effort drives workspace configuration of human brain functional networks
Manfred G Kitzbichler, Richard N A Henson, Marie L Smith, et al.
Psychopharmacology
|
July 25, 2007
High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans
Barry V O'Neill, Rodney J Croft, Sumie Leung, et al.
Drug Discovery Today
|
September 10, 2019
Cholinergic muscarinic M<sub>1</sub> and M<sub>4</sub> receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
Daniel Erskine, John-Paul Taylor, Geor Bakker, et al.
Hormones and Behavior
|
August 19, 2008
Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women
Cali F Bartholomeusz, Keith A Wesnes, Jayashri Kulkarni, et al.
Drug Discovery Today
|
November 28, 2015
Assessment of cognitive safety in clinical drug development
Jonathan P Roiser, Pradeep J Nathan, Adrian P Mander, et al.
Page
of 14